FDA Seeks Input on Early-Phase Ibogaine Trial Designs
FDA is seeking public input on potential early-phase clinical trial designs for ibogaine drugs, including proposals for cautious dose escalation, intensive cardiac and neurologic monitoring and independent safety oversight.
In a request for information (RFI), CDER says it is seeking comments and data on appropriate patient populations, dosing, care settings, eligibility criteria, stopping rules and other safeguards for clinical studies of ibogaine, a psychedelic drug being investigated for serious mental health and substance use disorders. Among the approaches under consideration is the use of small, sequential dose-ascending groups, with starting doses justified by available data and not exceeding 10 mg/kg, it says.
“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches,” CDER director Michael Davis is quoted in a notice as saying. “With ibogaine, there are important scientific questions as well as serious safety concerns.”
The RFI is part of the Trump administration’s broader effort to accelerate development of psychedelic therapies. An April executive order directed federal agencies to speed research into psychedelic medicines for serious mental illness.
FDA in July finalized its guidance (see earlier story) on clinical investigations of psychedelic drugs and has allowed an early-phase study of noribogaine hydrochloride, an ibogaine derivative, to proceed under an IND as a potential treatment for alcohol use disorder. The guidance details the agency’s current recommendations for developing psychedelic drug products, and provides sponsors with the most comprehensive roadmap to date for addressing manufacturing, nonclinical testing, clinical trial design, abuse potential, and long-term safety considerations. The guidance acknowledges the growing interest in psychedelic therapies for psychiatric and neurological disorders while emphasizing that these products will be held to the same statutory standards for safety and effectiveness as other prescription drugs.
Among the document's most significant recommendations are new expectations for addressing the unique challenges posed by psychedelic drugs in clinical development, particularly the difficulty of maintaining treatment blinding in clinical trials because of the drugs' well-known psychoactive effects. FDA says sponsors should design studies to minimize "functional unblinding," in which participants, investigators, or therapists recognize whether a patient received active treatment because of the drug's perceptual and psychological effects.
FDA said information submitted in response to the RFI could help the agency better characterize ibogaine’s potential benefits and risks and shape future drug-development approaches.
Comments are due 11/20 under docket FDA-2026-N-10429.